Abstract
5-Lipoxygenase, which leads to the biosynthesis of proinflammatory lipid mediators, is involved in the pathogenesis of cancer. Experimental studies have demonstrated that 5-lipoxygenase inhibitors have antitumoral properties. Here, we describe the compelling evidence that 5-lipoxygenase inhibition is a rational therapy for certain cancers and for adjuvant approaches to cancer therapy.
Original language | English |
---|---|
Pages (from-to) | 459-461 |
Number of pages | 3 |
Journal | Letters in Drug Design and Discovery |
Volume | 3 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2006 |
Keywords
- 5-lipoxygenase
- Cancer therapy
- Eicosanoids
- Lipoxygenase inhibitors
ASJC Scopus subject areas
- Pharmaceutical Science
- Drug Discovery
- Molecular Medicine